Interleukin 21 News and Research

RSS

Jamaican fruit bat's response to SARS-CoV-2 adapted to human

In a recent study posted to the bioRxiv* server, researchers examined the vulnerability of Jamaican fruit bats (Artibeus jamaicensis) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Feb 2023

Vaccine features that could induce durable humoral immune responses against SARS-CoV-2

A new study explored key vaccine features which could help induce and preserve humoral immunity against SARS-CoV-2 infection.

11 May 2022

'Combination' adjuvant may boost the protective power of vaccines

Scientists at La Jolla Institute for Immunology and Massachusetts Institute of Technology, have found a possible way to improve the effectiveness of COVID-19 vaccines-;and any vaccine.

4 Dec 2021

Metabolic restoration as a therapeutic approach to promote natural immune protection against HIV

The human immunodeficiency virus (HIV-1) particularly attacks CD4 lymphocytes, a type of white blood cell considered to be the conductor of the immune system.

15 Oct 2021

Potent antibodies against SARS-CoV-2 can be produced without T follicular helper cells, suggests study

It has been uncertain whether antibodies produced via this non-canonical pathway are protective against SARS-CoV-2. In a new study, recently released as a preprint on the bioRxiv*server, the neutralization potency of these antibodies is compared with those traditionally produced in germinal center-based antiviral responses.

15 Jun 2021

Translational research results in promising combination therapeutic candidate for type 1 diabetes

Translational research led by scientists at La Jolla Institute for Immunology (LJI) has resulted in a promising combination therapeutic candidate for adults with recent-onset type 1 diabetes.

9 Mar 2021

HIV: New therapeutic approach to restore the effectiveness of immune cells

Prompted by the need to improve conventional treatments for people infected with the human immunodeficiency virus (HIV-1), a team from the Institut national de la recherche scientifique has identified a therapeutic approach to restore the effectiveness of immune cells.

8 Feb 2021

IL-21 protein is a major part of immune response to chronic infections in the central nervous system

Researchers at Penn State College of Medicine now better understand the role of a protein, interleukin-21 (IL-21), in the immune system response to infections in the nervous system.

6 Oct 2020

Study reveals how B cells react to SARS-CoV-2

In an exciting immunological medRxiv preprint paper, researchers from Germany and Russia analyzed adaptive immune response in severely affected patients with coronavirus disease (COVID-19). They demonstrated a protracted immune reaction characterized by egress of B lymphocytes into the blood.

9 Sep 2020

New method helps pinpoint new potential therapeutic targets for lupus

A team of researchers from Children's Hospital of Philadelphia (CHOP) used a new method of pinpointing potential disease-causing changes in the genome to identify two new potential therapeutic targets for lupus, while also paving the way for more accurately identifying disease-causing variations in other autoimmune disorders.

8 Jul 2020

Combination produces more proliferative, enduring central memory T cells for cellular therapy

Treating T cells harvested from a patient with a combination of an epigenetic drug and a cytokine while expanding the cells in the lab re-programs them into a stronger T cell type that persists longer than its comrades, researchers at The University of Texas MD Anderson Cancer Center report in Cancer Immunology Research, a journal of the American Association for Cancer Research.

25 Mar 2020

Research findings may pave way for innovative treatments of multiple sclerosis

Researchers at the Research Center for Immunotherapy and the Focus Program Translational Neurosciences of Johannes Gutenberg University Mainz have identified a new mechanism that is involved in the development of autoimmune diseases.

14 Sep 2016

Oncologists combine two different types of immunotherapy to successfully treat metastatic melanoma

Oncologists at the Fred Hutchinson Cancer Research Center have successfully treated a patient with metastatic melanoma by combining two different types of immunotherapy. Cassian Yee and colleagues describe their approach in a paper, "Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient," that will be published online May 30 in The Journal of Experimental Medicine.

30 May 2016

Scientists describe interplay of four molecules that trigger, govern antibody production in immune cells

Australian scientists have described an exquisitely balanced interplay of four molecules that trigger and govern antibody production in immune cells. As well as being an important basic science discovery, it helps explain why people with mutations in any one of the associated genes cannot fight infection effectively, and develop rare and crippling immunodeficiency disorders.

18 Nov 2013

Lupus Foundation of America announces Career Development Award and new summer fellowships

The Lupus Foundation of America, the only national force dedicated to solving the cruel mystery of lupus, announced recipients of five new summer fellowships and the Foundation's first-ever Career Development Award.

3 Jun 2013

Research describes advantages of new vaccine adjuvant

New research from the laboratory of Dr. Elizabeth Leadbetter at the Trudeau Institute may lead to a whole new class of vaccines. Dr. Leadbetter's lab has discovered new properties of a potential vaccine adjuvant that suggest it could be useful for enhancing protection against a number of different infections.

13 Dec 2011

New Crohn’s disease therapy on its way

In a new study on a drug called Stelara (ustekinumab) it was seen that 40% patients with moderate to severe Crohn's disease responded. Stelara, which is already approved to treat psoriasis, is a human interleukin (IL)-12 and IL-23 antagonist marketed by Centocor Ortho Biotech Inc. The study findings were presented at Digestive Disease Week 2011.

11 May 2011

Researchers investigate mechanism of immune system to decipher gut-dwelling worms

A billion people living in underdeveloped areas around the world are infected with parasitic helminthes, worms that survive by residing in and feeding on their hosts. These infestations can cause chronic intestinal (and occasionally systemic) illnesses leading to long-term disability. Irah King and Markus Mohrs, biomedical researchers at the Trudeau Institute, are investigating illnesses caused by these gut-dwelling worms in an effort to decipher how immune cells send and receive signals that determine the specific immune response to mount.

12 Oct 2010

ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial

ZymoGenetics, Inc. today announced positive survival data from a Phase 2a clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. Median overall survival was 12.4 months, and the percentage of patients surviving at 12 months was 53%.

29 Sep 2010

ZymoGenetics second-quarter net loss declines to $3.8 million

ZymoGenetics, Inc. today reported substantially improved financial results for the quarter ended June 30, 2010. For the second quarter of 2010, the company's net loss declined to $3.8 million, or $0.04 per share, a $23.2 million improvement from the $27.0 million loss, or $0.39 per share, reported for the second quarter of 2009. The improvement resulted from higher revenues as well as reduced operating expenses.

4 Aug 2010